Dementia Clinical Trials

Find Dementia Clinical Trials Near You

Selective PET Imaging of Astrocytes and Microglia in Alzheimer's Disease

Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Observational
SUMMARY

Inflammation occurs in many brain diseases including Alzheimer's disease. In Alzheimer's disease, an abnormal protein called amyloid starts accumulating decades before the start of forgetfulness. However, scientists have reported that inflammation but not amyloid is linked to forgetfulness and the topography of brain inflammation and tau buildup are closely correlated in patients with mild cognitive impairment due to Alzheimer's disease. New medications are under development to help healing and prevent permanent damage in the brain. To see if inflammation is improving or getting worse with these medications, investigators can watch inside of the brain using a special camera called positron emission tomography (PET). It is currently possible to watch inflammation in the brain by taking pictures of a molecule called translocator protein (TSPO). But the problem is that by imaging TSPO, investigators can catch changes in more than one kind of cells. The information is not specific to each cell type. Such vague information is not completely useful to monitor the effect of new medications for inflammation. This proposal attempts to develop a novel method to capture changes in each of two major players in inflammation, microglia and astrocytes. To do so, investigators will take selective pictures of one cell type by using a novel imaging agent for PET. Investigators will also take PET pictures of TSPO. Investigators will process these two kinds of PET pictures using advanced mathematical methods and extract specific information on microglia and astrocytes. Our novel method will be useful to monitor new therapies to treat inflammation in the brain.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 90
Healthy Volunteers: t
View:

• Individuals of either sex, 50-90 years of age.

• Meeting research criteria for AD (McKhann, Knopman et al. 2011).

• With a CDR (Morris 1993) score of 1-3.

• Fluent in English or Spanish.

• Have sufficient communication and comprehension ability to consent to the performance of the study or have a legally authorized representative.

• Individuals of 18-90 years of age.

• Negative amyloid accumulation determined by PET (only for the comparison with AD).

• Fluent in English.

• Have enough communication and comprehension ability to consent to the performance of the study.

Locations
United States
Texas
Houston Methodist Research Institute
RECRUITING
Houston
Contact Information
Primary
Joseph C. Masdeu, MD, PhD
jcmasdeu@houstonmethodist.org
7134411150
Backup
Belen Pascual, PhD
bpascual@houstonmethodist.org
7134411150
Time Frame
Start Date: 2023-01-20
Estimated Completion Date: 2028-10-31
Participants
Target number of participants: 71
Treatments
Healthy subjects
Healthy subjects
Patients with Alzheimer's disease
Patients with Alzheimer's disease
Sponsors
Leads: The Methodist Hospital Research Institute

This content was sourced from clinicaltrials.gov